CN113024845A - Preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing - Google Patents
Preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing Download PDFInfo
- Publication number
- CN113024845A CN113024845A CN202110287289.XA CN202110287289A CN113024845A CN 113024845 A CN113024845 A CN 113024845A CN 202110287289 A CN202110287289 A CN 202110287289A CN 113024845 A CN113024845 A CN 113024845A
- Authority
- CN
- China
- Prior art keywords
- aqueous solution
- apd
- sodium alginate
- mol
- ultrapure water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 72
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 36
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 229910021642 ultra pure water Inorganic materials 0.000 claims abstract description 41
- 239000012498 ultrapure water Substances 0.000 claims abstract description 41
- 239000007864 aqueous solution Substances 0.000 claims abstract description 39
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000000661 sodium alginate Substances 0.000 claims abstract description 37
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 37
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000002243 precursor Substances 0.000 claims abstract description 32
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims abstract description 30
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims abstract description 22
- 241001122767 Theaceae Species 0.000 claims abstract description 13
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 13
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 13
- ZJSQZQMVXKZAGW-UHFFFAOYSA-N 2H-benzotriazol-4-ol hydrate Chemical compound O.OC1=CC=CC2=C1N=NN2 ZJSQZQMVXKZAGW-UHFFFAOYSA-N 0.000 claims abstract description 12
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 11
- KQIGMPWTAHJUMN-UHFFFAOYSA-N 3-aminopropane-1,2-diol Chemical compound NCC(O)CO KQIGMPWTAHJUMN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000012295 chemical reaction liquid Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000008367 deionised water Substances 0.000 claims description 20
- 229910021641 deionized water Inorganic materials 0.000 claims description 20
- 238000004108 freeze drying Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 15
- 238000000502 dialysis Methods 0.000 claims description 14
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 abstract description 2
- 239000000499 gel Substances 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- QYWVASPEUXEHSY-NNRNTGNWSA-N beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-(docosanoyl)sphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QYWVASPEUXEHSY-NNRNTGNWSA-N 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- -1 hydrazine compound Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/04—Alginic acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides a preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing, which comprises the following steps: (1) preparing Al-CDH from sodium alginate aqueous solution, hydroxybenzotriazole monohydrate HOBT, CDH and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC; (2) preparing an AL-CDH obtained in the step (1), ultrapure water and tea polyphenol into a hydrogel precursor A; (3) preparing sodium alginate aqueous solution, hydroxybenzotriazole monohydrate HOBT, 3-amino-1, 2-propylene glycol APD and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to obtain AL-APD; (4) preparing an AL-APD obtained in the step (3), a sodium periodate aqueous solution and acetic acid into a hydrogel precursor B; (5) and (3) uniformly mixing the hydrogel precursor A obtained in the step (2) and the hydrogel precursor B obtained in the step (4) to obtain the aldehyde hydrazine crosslinked antibacterial hydrogel dressing. The aldehyde hydrazine crosslinked antibacterial hydrogel dressing prepared by the invention can rapidly form gel at room temperature, effectively inhibit the proliferation of bacteria and has good biocompatibility.
Description
Technical Field
The invention relates to a hydrogel dressing, in particular to a preparation method of an aldehyde hydrazine crosslinked antibacterial hydrogel dressing.
Background
The skin is the largest organ of the human body and is often attacked by pathogenic microorganisms upon various injuries. Wound repair is a complex and dynamic process involving the combined action of various cells, factors, etc. The development of the wound dressing improves the process of wound repair, and the ideal wound dressing not only can be used as a physical barrier of the wound to avoid the wound from further damage and pollution, but also can provide a moist environment for the wound to accelerate the wound healing. The hydrogel is widely applied to the fields of external medical materials, tissue engineering scaffolds, biosensing, drug delivery and carriers and the like, and has been rapidly developed in recent years. However, the heterogeneity of the wound bed often makes it difficult for conventional dressings to fit the wound and makes it inconvenient to use. How to deal with various wounds and how to inject the quick-gelling antibacterial hydrogel becomes a development target of the antibacterial wound dressing. The existing research shows that hydrazyl bond crosslinked hydrogel can be formed by hydrazine compound and aldehyde compound, and the reaction and forming can be rapidly carried out at room temperature.
Disclosure of Invention
The invention aims to solve the technical problem of providing a preparation method of aldehyde-hydrazine crosslinked antibacterial hydrogel dressing, and the prepared aldehyde-hydrazine crosslinked antibacterial hydrogel dressing can rapidly form gel at room temperature, effectively inhibit the proliferation of bacteria and has good biocompatibility.
In order to solve the technical problems, the technical scheme of the invention is as follows:
a preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing comprises the following steps:
(1) adding a sodium alginate aqueous solution into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding carbohydrazide CDH to adjust the pH value to 5-6, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 6-18 hours to obtain a reaction liquid I, dialyzing the reaction liquid for 3-5 hours by using a dialysis bag, dialyzing the reaction liquid in deionized water for 1-3 days, and freeze-drying to obtain AL-CDH;
(2) mixing the AL-CDH obtained in the step (1), ultrapure water and tea polyphenol, standing overnight, dialyzing in deionized water, and freeze-drying to obtain a hydrogel precursor A;
(3) adding a sodium alginate aqueous solution into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding 3-amino-1, 2-propylene glycol APD to adjust the pH value to 5-6, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 6-18 hours to obtain a reaction liquid II, dialyzing the reaction liquid for 3-5 hours by using a dialysis bag, dialyzing the reaction liquid in deionized water for 1-3 days, and freeze-drying to obtain AL-APD;
(4) adding the AL-APD obtained in the step (3) into ultrapure water, stirring until the AL-APD is completely dissolved, adding a sodium periodate aqueous solution and acetic acid to react for 15-25 minutes to obtain a reaction liquid III, dialyzing the reaction liquid III in deionized water for 1-3 days, and freeze-drying to obtain a hydrogel precursor B;
(5) and (3) uniformly mixing the hydrogel precursor A obtained in the step (2) and the hydrogel precursor B obtained in the step (4) to obtain the aldehyde hydrazine crosslinked antibacterial hydrogel dressing.
Furthermore, in the step (1) of the invention, the concentration of the sodium alginate aqueous solution is 15% w/v, and the proportion of the sodium alginate, the ultrapure water, the HOBT, the CDH and the EDC is (0.5-1.5) mol, (0.5-1) L:1mol:0.4mol:0.4 mol.
Further, in the step (1) of the present invention, the cut-off molecular weight of the dialysis bag is 3500.
Furthermore, in the step (2) of the invention, the proportion of AL-CDH, ultrapure water and tea polyphenol is (0.5-1.5 mol) to (0.5-1) L (0.1-0.2 mol).
Furthermore, in the step (3) of the invention, the concentration of the sodium alginate aqueous solution is 15% w/v, and the proportion of the sodium alginate, the ultrapure water, the HOBT, the APD and the EDC is (0.5-1.5) mol, (0.5-1) L:1mol:0.3mol:0.3 mol.
Further, in step (3) of the present invention, the molecular weight cut-off of the dialysis bag is 3500.
Further, in the step (3) of the present invention, the concentration of the aqueous solution of sodium periodate is 0.5mM, and the ratio of the Al-APD, the ultrapure water, the aqueous solution of sodium periodate and the acetic acid is (0.5-1.5) mol (0.5-1) L:20mL:2.5 mol.
Further, in the step (5) of the present invention, the ratio of the hydrogel precursor A to the hydrogel precursor B is 1mol:1 mol.
Compared with the prior art, the invention has the following beneficial effects:
1. the hydrogel precursor A prepared in the preparation method disclosed by the invention contains hydrazine groups (the hydrazine groups are modified by coupling CDH), the hydrogel precursor B contains aldehyde groups (sodium periodate has oxidability on ortho-position hydroxyl groups, the hydroxyl groups of 3-amino-1, 2-propanediol are oxidized into the ortho-position aldehyde groups by using the sodium periodate), the hydrogel precursor A and the hydrogel precursor B are physically mixed to quickly form hydrazone bond crosslinked hydrogel at room temperature, and the hydrogel has injectability, so that the hydrogel dressing can be attached to various wounds in a personalized manner.
2. According to the invention, tea polyphenol is loaded on hydrogel, and the prepared hydrogel dressing has certain mechanical property, and can release tea polyphenol to play a good antibacterial role.
3. The sodium alginate used in the invention is derived from brown algae plants, is used as a natural polysaccharide biomaterial, and has good stability, solubility, viscosity and safety.
4. The raw materials used in the invention have good biocompatibility, so that the prepared hydrogel dressing also has good biocompatibility.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this application, illustrate embodiment(s) of the invention and together with the description serve to explain the principles of the invention:
FIG. 1 is a graph showing biocompatibility tests in examples 1 and 2 of the present invention.
Detailed Description
The present invention will be described in detail with reference to specific embodiments, which are illustrative of the invention and are not to be construed as limiting the invention.
Example 1
Preparing aldehyde hydrazine cross-linked antibacterial hydrogel dressing according to the following steps:
(1) adding a sodium alginate aqueous solution with the concentration of 15% w/v into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding carbohydrazide CDH to adjust the pH value to 5.8, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 12 hours to obtain a reaction liquid I, dialyzing the reaction liquid for 4 hours by using a dialysis bag with the molecular weight cutoff of 3500, dialyzing in deionized water for 2 days, and freeze-drying to obtain AL-CDH, wherein the ratio of sodium alginate to ultrapure water to HOBT to CDH to EDC is 1mol:0.8L:1mol:0.4mol:0.4 mol;
(2) mixing the AL-CDH, ultrapure water and tea polyphenol obtained in the step (1), standing overnight, dialyzing in deionized water, and freeze-drying to obtain a hydrogel precursor A, wherein the ratio of the AL-CDH, the ultrapure water and the tea polyphenol is 1mol:0.8L:0.1 mol;
(3) adding a sodium alginate aqueous solution with the concentration of 15% w/v into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding 3-amino-1, 2-propylene glycol APD to adjust the pH value to 5.8, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 12 hours to obtain a reaction liquid II, dialyzing the reaction liquid II in a dialysis bag with the molecular weight cutoff of 3500 for 4 hours, dialyzing in deionized water for 2 days, and freeze-drying to obtain AL-APD, wherein the ratio of the sodium alginate, the ultrapure water, the HOBT, the APD and the EDC is 1mol:0.8L:1mol:0.3mol:0.3 mol;
(4) adding the AL-APD obtained in the step (3) into ultrapure water, stirring until the AL-APD is completely dissolved, adding a 0.5mM sodium periodate aqueous solution and acetic acid to react for 20 minutes to obtain a third reaction solution, dialyzing the third reaction solution in deionized water for 2 days, and freeze-drying to obtain a hydrogel precursor B, wherein the ratio of the AL-APD, the ultrapure water, the sodium periodate aqueous solution and the acetic acid is 1mol:0.8L:20mL:2.5 mol;
(5) and (3) uniformly mixing the hydrogel precursor A obtained in the step (2) and the hydrogel precursor B obtained in the step (4) in a ratio of 1mol:1mol to obtain the aldehyde-hydrazine crosslinked antibacterial hydrogel dressing.
Example 2
Preparing aldehyde hydrazine cross-linked antibacterial hydrogel dressing according to the following steps:
(1) adding a sodium alginate aqueous solution with the concentration of 15% w/v into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding CDH to adjust the pH value to 5, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 6 hours to obtain a reaction solution I, dialyzing the reaction solution for 3 hours by using a dialysis bag with the molecular weight cutoff of 3500, dialyzing in deionized water for 1 day, and freeze-drying to obtain AL-CDH, wherein the ratio of sodium alginate, ultrapure water, HOBT, CDH and EDC is 0.5mol:1L:1mol:0.4mol:0.4 mol;
(2) mixing the AL-CDH, the ultrapure water and the tea polyphenol obtained in the step (1), standing overnight, dialyzing in deionized water, and freeze-drying to obtain a hydrogel precursor A, wherein the ratio of the AL-CDH, the ultrapure water and the tea polyphenol is 0.5mol:1L:0.2 mol;
(3) adding a sodium alginate aqueous solution with the concentration of 15% w/v into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding 3-amino-1, 2-propylene glycol APD to adjust the pH value to 5, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 6 hours to obtain a reaction liquid II, dialyzing the reaction liquid II in a dialysis bag with the molecular weight cutoff of 3500 for 3 hours, dialyzing in deionized water for 1 day, and freeze-drying to obtain AL-APD, wherein the ratio of the sodium alginate to the ultrapure water to the HOBT to the APD to the EDC is 0.5mol:1L:1mol:0.3 mol;
(4) adding the AL-APD obtained in the step (3) into ultrapure water, stirring until the AL-APD is completely dissolved, adding a 0.5mM sodium periodate aqueous solution and acetic acid to react for 15 minutes to obtain a third reaction solution, dialyzing the third reaction solution in deionized water for 1 day, and freeze-drying to obtain a hydrogel precursor B, wherein the ratio of the AL-APD, the ultrapure water, the sodium periodate aqueous solution and the acetic acid is 0.5mol:1L:20mL:2.5 mol;
(5) and (3) uniformly mixing the hydrogel precursor A obtained in the step (2) and the hydrogel precursor B obtained in the step (4) in a ratio of 1mol:1mol to obtain the aldehyde-hydrazine crosslinked antibacterial hydrogel dressing.
Example 3
Preparing aldehyde hydrazine cross-linked antibacterial hydrogel dressing according to the following steps:
(1) adding a sodium alginate aqueous solution with the concentration of 15% w/v into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding CDH to adjust the pH value to 6, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 18 hours to obtain a reaction solution I, dialyzing the reaction solution for 5 hours by using a dialysis bag with the molecular weight cutoff of 3500, dialyzing in deionized water for 3 days, and freeze-drying to obtain AL-CDH, wherein the ratio of sodium alginate, ultrapure water, HOBT, CDH and EDC is 1.5mol:0.5L:1mol:0.4mol:0.4 mol;
(2) mixing the AL-CDH, the ultrapure water and the tea polyphenol obtained in the step (1), standing overnight, dialyzing in deionized water, and freeze-drying to obtain a hydrogel precursor A, wherein the ratio of the AL-CDH, the ultrapure water and the tea polyphenol is 1.5mol:0.5L:0.1 mol;
(3) adding a sodium alginate aqueous solution with the concentration of 15% w/v into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding 3-amino-1, 2-propylene glycol APD to adjust the pH value to 6, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 18 hours to obtain a reaction liquid II, dialyzing the reaction liquid II in a dialysis bag with the molecular weight cutoff of 3500 for 5 hours, dialyzing in deionized water for 3 days, and freeze-drying to obtain AL-APD, wherein the ratio of the sodium alginate to the ultrapure water to the HOBT to the APD to the EDC is 1.5mol:0.5L:1mol:0.3mol:0.3 mol;
(4) adding the AL-APD obtained in the step (3) into ultrapure water, stirring until the AL-APD is completely dissolved, adding a 0.5mM sodium periodate aqueous solution and acetic acid to react for 25 minutes to obtain a third reaction solution, dialyzing the third reaction solution in deionized water for 3 days, and freeze-drying to obtain a hydrogel precursor B, wherein the ratio of the AL-APD, the ultrapure water, the sodium periodate aqueous solution and the acetic acid is 1.5mol:0.5L:20mL:2.5 mol;
(5) and (3) uniformly mixing the hydrogel precursor A obtained in the step (2) and the hydrogel precursor B obtained in the step (4) in a ratio of 1mol:1mol to obtain the aldehyde-hydrazine crosslinked antibacterial hydrogel dressing.
Antibacterial testing
1. Dispersing the strain in sterile water with inoculating loop, filtering, and making into 106-108CFU/mL of bacterial liquid.
2. 0.4mL of the suspension was injected into each dish using a Pasteur pipette.
3. 20mL of a molten agar medium (about 45 ℃) was poured into each dish, and the cells and the medium were mixed uniformly and cooled.
4. 200. mu.L of the aldehyde hydrazine cross-linking type antibacterial hydrogel dressing prepared in example 1 was placed in the center of the medium plate, and the lid was closed.
5. Culturing at 37 deg.C for 3d, and observing the presence and size of the antibacterial zone around the aldehyde-hydrazine cross-linked antibacterial hydrogel dressing.
The test results are: the embodiment 1 shows the inhibition zone, and the diameter of the inhibition zone is 16.2mm, which proves that the aldehyde-hydrazine crosslinked antibacterial hydrogel dressing prepared by the invention has better antibacterial performance.
Biocompatibility testing
Cytotoxicity of the aldehyde hydrazine cross-linked antibacterial hydrogel dressings prepared in the examples 1 and 2 in 12, 24, 48 and 72h was detected by a CCK-8 method.
The test results are shown in fig. 1: the cytotoxicity of the embodiment 1 and the cytotoxicity of the embodiment 2 are both 1 grade, and the fact that the aldehyde hydrazine cross-linked antibacterial hydrogel dressing prepared by the invention has better biocompatibility is proved.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (8)
1. A preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing is characterized by comprising the following steps: the method comprises the following steps:
(1) adding a sodium alginate aqueous solution into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding carbohydrazide CDH to adjust the pH value to 5-6, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 6-18 hours to obtain a reaction liquid I, dialyzing the reaction liquid for 3-5 hours by using a dialysis bag, dialyzing the reaction liquid in deionized water for 1-3 days, and freeze-drying to obtain AL-CDH;
(2) mixing the AL-CDH obtained in the step (1), ultrapure water and tea polyphenol, standing overnight, dialyzing in deionized water, and freeze-drying to obtain a hydrogel precursor A;
(3) adding a sodium alginate aqueous solution into ultrapure water, stirring until the sodium alginate aqueous solution is completely dissolved, adding hydroxybenzotriazole monohydrate HOBT, standing overnight, adding 3-amino-1, 2-propylene glycol APD to adjust the pH value to 5-6, then adding 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride EDC to react for 6-18 hours to obtain a reaction liquid II, dialyzing the reaction liquid for 3-5 hours by using a dialysis bag, dialyzing the reaction liquid in deionized water for 1-3 days, and freeze-drying to obtain AL-APD;
(4) adding the AL-APD obtained in the step (3) into ultrapure water, stirring until the AL-APD is completely dissolved, adding a sodium periodate aqueous solution and acetic acid to react for 15-25 minutes to obtain a reaction liquid III, dialyzing the reaction liquid III in deionized water for 1-3 days, and freeze-drying to obtain a hydrogel precursor B;
(5) and (3) uniformly mixing the hydrogel precursor A obtained in the step (2) and the hydrogel precursor B obtained in the step (4) to obtain the aldehyde hydrazine crosslinked antibacterial hydrogel dressing.
2. The method for preparing the aldehyde hydrazine crosslinked antibacterial hydrogel dressing according to claim 1, wherein the method comprises the following steps: in the step (1), the concentration of the sodium alginate aqueous solution is 15% w/v, and the proportion of the sodium alginate, the ultrapure water, the HOBT, the CDH and the EDC is (0.5-1.5) mol, (0.5-1) L:1mol:0.4mol:0.4 mol.
3. The method for preparing the aldehyde hydrazine crosslinked antibacterial hydrogel dressing according to claim 1, wherein the method comprises the following steps: in the step (1), the molecular weight cut-off of the dialysis bag is 3500.
4. The method for preparing the aldehyde hydrazine crosslinked antibacterial hydrogel dressing according to claim 1, wherein the method comprises the following steps: in the step (2), the proportion of AL-CDH, ultrapure water and tea polyphenol is (0.5-1.5 mol) to (0.5-1) L (0.1-0.2 mol).
5. The method for preparing the aldehyde hydrazine crosslinked antibacterial hydrogel dressing according to claim 1, wherein the method comprises the following steps: in the step (3), the concentration of the sodium alginate aqueous solution is 15% w/v, and the proportion of the sodium alginate, the ultrapure water, the HOBT, the APD and the EDC is (0.5-1.5) mol, (0.5-1) L:1mol:0.3mol:0.3 mol.
6. The method for preparing the aldehyde hydrazine crosslinked antibacterial hydrogel dressing according to claim 1, wherein the method comprises the following steps: in the step (3), the molecular weight cut-off of the dialysis bag is 3500.
7. The method for preparing the aldehyde hydrazine crosslinked antibacterial hydrogel dressing according to claim 1, wherein the method comprises the following steps: in the step (3), the concentration of the sodium periodate aqueous solution is 0.5mM, and the proportion of the AL-APD, the ultrapure water, the sodium periodate aqueous solution and the acetic acid is (0.5-1.5) mol, (0.5-1) L:20mL:2.5 mol.
8. The method for preparing the aldehyde hydrazine crosslinked antibacterial hydrogel dressing according to claim 1, wherein the method comprises the following steps: in the step (5), the proportion of the hydrogel precursor A to the hydrogel precursor B is 1mol:1 mol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110287289.XA CN113024845A (en) | 2021-03-17 | 2021-03-17 | Preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110287289.XA CN113024845A (en) | 2021-03-17 | 2021-03-17 | Preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113024845A true CN113024845A (en) | 2021-06-25 |
Family
ID=76471308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110287289.XA Pending CN113024845A (en) | 2021-03-17 | 2021-03-17 | Preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113024845A (en) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002006373A1 (en) * | 2000-07-17 | 2002-01-24 | University Of Utah Research Foundation | Hydrogel films and methods of making and using therefor |
| US7125860B1 (en) * | 2000-08-31 | 2006-10-24 | Fidia Farmaceutici S.P.A. | Cross-linked derivatives of hyaluronic acid |
| US20100233267A1 (en) * | 2007-02-01 | 2010-09-16 | The Research Foundation Of State University Of New York | Composite hydrogel |
| CN103910894A (en) * | 2014-03-28 | 2014-07-09 | 西安交通大学 | Preparation method of injectable natural polysaccharide self-healing hydrogel |
| EP3156044A1 (en) * | 2015-10-16 | 2017-04-19 | Merz Pharma GmbH & Co. KGaA | In situ cross-linkable polysaccharide compositions and uses thereof |
| CN107964056A (en) * | 2017-11-15 | 2018-04-27 | 华东理工大学 | Preparation method, raw material, product and the application of optical coupling cross-linked hydrogel material |
| CN108395549A (en) * | 2018-03-27 | 2018-08-14 | 河南省科学院能源研究所有限公司 | A kind of high-intensity and high-tenacity antimicrobial form polyvinyl alcohol hydrogel and preparation method thereof |
| CN108434514A (en) * | 2018-04-18 | 2018-08-24 | 华中农业大学 | It is a kind of to have both antibacterial and biological inducing action collagen hydrogel preparation method |
| CN110498936A (en) * | 2019-07-15 | 2019-11-26 | 北京化工大学 | A kind of preparation method of Sodium Hyaluronate/sodium alginate injection-type composite hydrogel |
| CN110698692A (en) * | 2019-10-28 | 2020-01-17 | 四川大学 | Preparation method and application of self-healing sodium alginate/gelatin-based hydrogel material capable of spraying to form film |
| CN110698680A (en) * | 2019-10-28 | 2020-01-17 | 四川大学 | Self-healing sodium alginate/gelatin-based hydrogel material capable of spraying to form film |
| WO2021007899A1 (en) * | 2019-07-15 | 2021-01-21 | 浙江工业大学 | Injectable hydrogel material and preparation method therefor and use thereof |
-
2021
- 2021-03-17 CN CN202110287289.XA patent/CN113024845A/en active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002006373A1 (en) * | 2000-07-17 | 2002-01-24 | University Of Utah Research Foundation | Hydrogel films and methods of making and using therefor |
| US7125860B1 (en) * | 2000-08-31 | 2006-10-24 | Fidia Farmaceutici S.P.A. | Cross-linked derivatives of hyaluronic acid |
| US20100233267A1 (en) * | 2007-02-01 | 2010-09-16 | The Research Foundation Of State University Of New York | Composite hydrogel |
| CN103910894A (en) * | 2014-03-28 | 2014-07-09 | 西安交通大学 | Preparation method of injectable natural polysaccharide self-healing hydrogel |
| EP3156044A1 (en) * | 2015-10-16 | 2017-04-19 | Merz Pharma GmbH & Co. KGaA | In situ cross-linkable polysaccharide compositions and uses thereof |
| CN107964056A (en) * | 2017-11-15 | 2018-04-27 | 华东理工大学 | Preparation method, raw material, product and the application of optical coupling cross-linked hydrogel material |
| CN108395549A (en) * | 2018-03-27 | 2018-08-14 | 河南省科学院能源研究所有限公司 | A kind of high-intensity and high-tenacity antimicrobial form polyvinyl alcohol hydrogel and preparation method thereof |
| CN108434514A (en) * | 2018-04-18 | 2018-08-24 | 华中农业大学 | It is a kind of to have both antibacterial and biological inducing action collagen hydrogel preparation method |
| CN110498936A (en) * | 2019-07-15 | 2019-11-26 | 北京化工大学 | A kind of preparation method of Sodium Hyaluronate/sodium alginate injection-type composite hydrogel |
| WO2021007899A1 (en) * | 2019-07-15 | 2021-01-21 | 浙江工业大学 | Injectable hydrogel material and preparation method therefor and use thereof |
| CN110698692A (en) * | 2019-10-28 | 2020-01-17 | 四川大学 | Preparation method and application of self-healing sodium alginate/gelatin-based hydrogel material capable of spraying to form film |
| CN110698680A (en) * | 2019-10-28 | 2020-01-17 | 四川大学 | Self-healing sodium alginate/gelatin-based hydrogel material capable of spraying to form film |
Non-Patent Citations (2)
| Title |
|---|
| HOZUMI, T，等: "Injectable Hydrogel with Slow Degradability Composed of Gelatin and Hyaluronic Acid Cross-Linked by Schiffs Base Formation", 《BIOMACROMOLECULES》 * |
| 侯一凡，等: "基于可逆共价酰腙键制备海藻酸水凝胶及其pH响应性研究", 《化工新型材料》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113577377B (en) | Antibacterial and anti-inflammatory hydrogel skin dressing with active oxygen elimination function and preparation method thereof | |
| He et al. | Multifunctional hydrogel with reactive oxygen species scavenging and photothermal antibacterial activity accelerates infected diabetic wound healing | |
| CN112121226B (en) | Composite hydrogel for promoting wound healing and preparation method and application thereof | |
| CN111154149A (en) | Hydrogel and preparation method and dressing thereof | |
| CN112480434B (en) | Copper ion antibacterial hydrogel and preparation method and application thereof | |
| CN110680952B (en) | Injectable medical wound dressing with antibacterial function | |
| KR20060135761A (en) | Wound dressings comprising a protein polymer and a polyfunctional spacer | |
| US10836872B2 (en) | Visible light-curable water-soluble chitosan derivative, chitosan hydrogel, and preparation method therefor | |
| CN111732737A (en) | Degradable self-healing chitosan composite aldehyde guar gum gel and preparation method and application thereof | |
| CN115124738B (en) | Double-layer bionic drug-loaded hydrogel and preparation and application thereof | |
| CN115429935B (en) | Injectable cross-linked chondroitin sulfate hydrogel and preparation method thereof | |
| CN108210985A (en) | A kind of high-strength medical hydrogel based on human-like collagen and preparation method thereof | |
| CN112876694A (en) | Preparation method and application of acrylic acid/epsilon-polylysine adhesive antibacterial hydrogel | |
| CN116650710A (en) | Mussel inspired multifunctional double-network crosslinked hydrogel wound dressing | |
| CN107469137B (en) | Injectable hemostatic hydrogel material and preparation method and application thereof | |
| Nath et al. | Multifunctional mussel‐inspired Gelatin and Tannic acid‐based hydrogel with pH‐controllable release of vitamin B12 | |
| CN115926200A (en) | Preparation method and application of enzyme-catalyzed double-crosslinked polymer composite hydrogel material | |
| Zhang et al. | In situ gelation strategy based on ferrocene-hyaluronic acid organic copolymer biomaterial for exudate management and multi-modal wound healing | |
| CN115536919A (en) | Modified chitosan adhesive hydrogel and preparation method and application thereof | |
| CN113509591A (en) | Antibacterial cationic injectable hydrogel dressing and preparation method thereof | |
| Zhao et al. | Injectable Double Crosslinked Hydrogel‐Polypropylene Composite Mesh for Repairing Full‐Thickness Abdominal Wall Defects | |
| CN113274541A (en) | Antibacterial collagen-based medical material and preparation method thereof | |
| CN113024845A (en) | Preparation method of aldehyde hydrazine cross-linked antibacterial hydrogel dressing | |
| CN115850733A (en) | Injectable nano clay hydrogel and preparation method and application thereof | |
| CN115581795A (en) | Antibacterial soft tissue adhesion protective agent and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210625 |